De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine

Abstract

Background:

Dalfampridine extended release (DAL) is a broad-spectrum voltage-gated potassium channel blocker that is indicated in multiple sclerosis to improve the nerve conduction of demyelinated axons. Seizures are a known side effect of DAL, which is contraindicated in patients with a history of epilepsy.

Objective:

Three cases of multiple sclerosis (MS) with de novo convulsive status epilepticus (CSE) probably related to dalfampridine administration are described.

Methods:

No patients had a history of seizures or renal impairment. Biological tests were normal. A brain magnetic resonance imaging (MRI) showed diffuse cortical and subcortical atrophy without active inflammatory lesions.

Results:

All three patients presented with CSE that was attributed to DAL and so was discontinued.

Conclusion:

These case reports illustrate that, aside from seizures, de novo CSE is a potential complication of MS patients treated with DAL.